Ju Huang, Wenjuan Liu, Li Huang, Jianxing Ruan, Qianwen Huang, Lijia Zhang, Fenghua Liu
{"title":"Bladder haematoma after transvaginal ultrasound-guided oocyte retrieval: a retrospective analysis and comprehensive review of the literature.","authors":"Ju Huang, Wenjuan Liu, Li Huang, Jianxing Ruan, Qianwen Huang, Lijia Zhang, Fenghua Liu","doi":"10.1080/14647273.2025.2488770","DOIUrl":null,"url":null,"abstract":"<p><p>Bladder hematoma following transvaginal ultrasound-guided oocyte retrieval (TVOR) is rare. We conducted a retrospective analysis of 33,271 patients who underwent TVOR procedures during in vitro fertilization and embryo transfer (IVF-ET) at our centre between January 2015 and June 2023. Additionally, a systematic literature search on bladder haematoma after TVOR was performed. Data on clinical symptoms, diagnostic processes, and treatment interventions for patients with bladder injurie or haematoma were collected and analyzed. We identified six cases (0.018%) of bladder injury following TVOR procedures at our centre. Nine studies reporting 12 cases of bladder haematoma, yielding a pooled incidence of approximately 0.02%. Bladder haematoma occurred at various times after the procedure, ranging from immediate to a maximum of seven days post TVOR. Of the 18 cases examined, four patients received conventional conservative treatment, while 12 patients underwent urinary catheter irrigation and drainage. The most common clinical symptoms included lower abdominal pain, urinary frequency, dysuria, visible haematuria, and urinary retention. Bladder haematoma resulting from bladder injury after TVOR is a rare complication. To reduce the risks associated with such complications, it is crucial to develop protocols that ensure appropriate prophylaxis, monitoring, and treatment for patients undergoing TVOR procedures.</p>","PeriodicalId":13006,"journal":{"name":"Human Fertility","volume":"28 1","pages":"2488770"},"PeriodicalIF":2.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Fertility","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14647273.2025.2488770","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Bladder hematoma following transvaginal ultrasound-guided oocyte retrieval (TVOR) is rare. We conducted a retrospective analysis of 33,271 patients who underwent TVOR procedures during in vitro fertilization and embryo transfer (IVF-ET) at our centre between January 2015 and June 2023. Additionally, a systematic literature search on bladder haematoma after TVOR was performed. Data on clinical symptoms, diagnostic processes, and treatment interventions for patients with bladder injurie or haematoma were collected and analyzed. We identified six cases (0.018%) of bladder injury following TVOR procedures at our centre. Nine studies reporting 12 cases of bladder haematoma, yielding a pooled incidence of approximately 0.02%. Bladder haematoma occurred at various times after the procedure, ranging from immediate to a maximum of seven days post TVOR. Of the 18 cases examined, four patients received conventional conservative treatment, while 12 patients underwent urinary catheter irrigation and drainage. The most common clinical symptoms included lower abdominal pain, urinary frequency, dysuria, visible haematuria, and urinary retention. Bladder haematoma resulting from bladder injury after TVOR is a rare complication. To reduce the risks associated with such complications, it is crucial to develop protocols that ensure appropriate prophylaxis, monitoring, and treatment for patients undergoing TVOR procedures.
期刊介绍:
Human Fertility is a leading international, multidisciplinary journal dedicated to furthering research and promoting good practice in the areas of human fertility and infertility. Topics included span the range from molecular medicine to healthcare delivery, and contributions are welcomed from professionals and academics from the spectrum of disciplines concerned with human fertility. It is published on behalf of the British Fertility Society.
The journal also provides a forum for the publication of peer-reviewed articles arising out of the activities of the Association of Biomedical Andrologists, the Association of Clinical Embryologists, the Association of Irish Clinical Embryologists, the British Andrology Society, the British Infertility Counselling Association, the Irish Fertility Society and the Royal College of Nursing Fertility Nurses Group.
All submissions are welcome. Articles considered include original papers, reviews, policy statements, commentaries, debates, correspondence, and reports of sessions at meetings. The journal also publishes refereed abstracts from the meetings of the constituent organizations.